Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The profile of cognitive impairments in chronic ketamine users
Xiaoyin Ke, Yi� Ding, Ke Xu, et al.
Psychiatry Research (2018) Vol. 266, pp. 124-131
Closed Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Panos Zanos, Ruin Moaddel, Patrick J. Morris, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 3, pp. 621-660
Open Access | Times Cited: 938
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 160
Molecular mechanism of programmed cell death in drug-induced neuronal damage: a special focus on ketamine-induced neurotoxicity
Peipei Wang, Tong Niu, D K Huang, et al.
Toxicology (2025) Vol. 513, pp. 154102-154102
Closed Access | Times Cited: 1
The clinical toxicology of ketamine
Leo J. Schep, Robin J Slaughter, Martin Watts, et al.
Clinical Toxicology (2023) Vol. 61, Iss. 6, pp. 415-428
Closed Access | Times Cited: 29
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
Gilly Wolf, Sandeep Singh, Karin Blakolmer, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 44-58
Closed Access | Times Cited: 36
Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder
Wei Zheng, Yanling Zhou, Weijian Liu, et al.
Journal of Affective Disorders (2018) Vol. 246, pp. 241-247
Closed Access | Times Cited: 57
Gulf War Illness: Mechanisms Underlying Brain Dysfunction and Promising Therapeutic Strategies
B.R. Dickey, Leelavathi N. Madhu, Ashok K. Shetty
Pharmacology & Therapeutics (2020) Vol. 220, pp. 107716-107716
Open Access | Times Cited: 46
Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling
Yayan Luo, Yu Yang, Min-Ling Zhang, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 9, pp. 4702-4718
Closed Access | Times Cited: 41
Th17 Cells in Depression: Are They Crucial for the Antidepressant Effect of Ketamine?
Meiying Cui, Wanlin Dai, Jing Kong, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 33
Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study
Lucas Araújo-de-Freitas, Cassio Santos‐Lima, Euclides Mendonça-Filho, et al.
Psychiatry Research (2021) Vol. 303, pp. 114058-114058
Closed Access | Times Cited: 32
Whole-brain mapping reveals the divergent impact of ketamine on the dopamine system
Malika S. Datta, Yannan Chen, Shradha Chauhan, et al.
Cell Reports (2023) Vol. 42, Iss. 12, pp. 113491-113491
Open Access | Times Cited: 13
Hydroxynorketamine, but not ketamine, acts via α7 nicotinic acetylcholine receptor to control presynaptic function and gene expression
Debarpan Guhathakurta, Aneta Petrušková, Enes Yağız Akdaş, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Maxwell Zachary Price, Richard L. Price
Biomarkers in Neuropsychiatry (2024) Vol. 11, pp. 100104-100104
Open Access | Times Cited: 4
Protective Effects of Trolox on Ketamine-Induced Memory Impairments and Morphological Changes in the Brain
Emre Uyar, Meral Erdinç, İlker Kelle, et al.
International Journal of Pharmacology (2025) Vol. 21, Iss. 1, pp. 27-36
Closed Access
Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
Xiaofeng Lan, Chengyu Wang, Fan Zhang, et al.
Child and Adolescent Psychiatry and Mental Health (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 12
Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study
Jan van Amsterdam, Wim van den Brink
Expert Opinion on Drug Safety (2021) Vol. 21, Iss. 1, pp. 83-94
Closed Access | Times Cited: 23
Tau protein plays a role in the mechanism of cognitive disorders induced by anesthetic drugs
Zheping Chen, Shenghan Wang, Zhaoqian Meng, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 10
Widespread reductions in cortical thickness following ketamine abuse
Jinsong Tang, Qiuxia Wu, Qi Chang, et al.
Journal of Psychiatry and Neuroscience (2024) Vol. 49, Iss. 3, pp. E182-E191
Open Access | Times Cited: 3
R-(−)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder1
Jeffrey M. Witkin, Jay Kranzler, Kyle Kaniecki, et al.
Pharmacology Biochemistry and Behavior (2020) Vol. 194, pp. 172927-172927
Closed Access | Times Cited: 25
Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders
Vern Lewis, Brandon Rodrigue, Emily Arsenault, et al.
Journal of Neurochemistry (2022) Vol. 166, Iss. 1, pp. 10-23
Closed Access | Times Cited: 14
Astrocyte Activation, but not Microglia, Is Associated with the Experimental Mouse Model of Schizophrenia Induced by Chronic Ketamine
Ying Wei, Li Xiao, Weihao Fan, et al.
Journal of Molecular Neuroscience (2022) Vol. 72, Iss. 9, pp. 1902-1915
Closed Access | Times Cited: 14
Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review
Danika Dai, Courtney Miller, Violeta Valdivia, et al.
BMC Psychiatry (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Increased use of ketamine for the treatment of depression: Benefits and concerns
Kyoung‐Sae Na, Yong‐Ku Kim
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 104, pp. 110060-110060
Closed Access | Times Cited: 20
Recovery of cognitive functioning following abstinence from ketamine
Wai Kwong Tang, Chieh Grace Lau, Gábor S. Ungvári, et al.
Addictive Behaviors (2019) Vol. 99, pp. 106081-106081
Closed Access | Times Cited: 17
Whole-brain mapping reveals the divergent impact of ketamine on the dopamine system
Malika S. Datta, Yannan Chen, Shradha Chauhan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top